Skip to content

US · IMVT · BIOTECHNOLOGY

Immunovant, Inc. (IMVT) intrinsic value and stock valuation

$31.77as of 2026-11-21 · Mkt cap 8.25B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immunovant, Inc. DCF and intrinsic value

InvestorsCraft values IMVT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IMVT’s statements →

Immunovant, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Durham, NY 27713 immunovant.com

How the business is doing

Fiscal 2018–2026, USD

Revenue
$0.00
20182026
Net income
-$-505.61M
20182026
Free cash flow
-$-407.32M
20182026
Total equity
$852.6M+16.8% 5y CAGRd
20182026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-532.9M-$-438.15M-$-270.21M-$-208.28M-$-156.03M
Net income-$-505.61M-$-413.84M-$-259.34M-$-210.96M-$-156.73M
EPSd-$-2.77M-$-2.73M-$-1.88M-$-1.71M-$-1.43M
Operating cash flow-$-407.31M-$-375.87M-$-214.23M-$-188.19M-$-106.11M
Capital expenditure-$-10K-$-760K-$-360K-$-200K-$-250K
Free cash flow-$-407.32M-$-376.63M-$-214.59M-$-188.39M-$-106.37M
Total assets$957.6M$776.2M$666.7M$405.8M$515.6M
Total debt$70K$100K$140K$1.22M$2.36M
Net debt-$-902.04M-$-713.87M-$-635.23M-$-375.31M-$-491.45M
Total equity$852.6M$707.5M$617.8M$362.5M$469.8M
Cash and short-term investments$902.1M$714M$635.4M$376.5M$493.8M
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$410K$0.00$0.00$0.00$0.00
Gross profit-$-410K$0.00$0.00$0.00$0.00
Research and development expenses$456.7M$360.9M$212.9M$160.3M$101.8M
Selling, general and administrative expenses$76.2M$77.2M$57.3M$48M$54.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$532.9M$438.2M$270.2M$208.3M$156M
Cost and expenses$532.9M$438.2M$270.2M$208.3M$156M
Interest income$25.3M$24.7M$25M$7.58M$0.00
Interest expense$0.00$0.00$0.00$12.5M$0.00
Depreciation and amortization$410K$380K$230K$190K$130K
Ebitda-$-504.98M-$-412.57M-$-258.54M-$-198.28M-$-156.69M
Operating income-$-532.9M-$-438.15M-$-270.21M-$-208.28M-$-156.03M
Total other income/expenses, net$27.5M$25.2M$11.4M-$-2.67M-$-780K
Income before tax-$-505.39M-$-412.95M-$-258.77M-$-210.95M-$-156.81M
Income tax expense$210K$890K$570K$10K-$-80K
Net income-$-505.61M-$-413.84M-$-259.34M-$-210.96M-$-156.73M
Weighted average shares outstanding$182.4M$151.6M$138.1M$123.1M$109.7M
Weighted average diluted shares outstanding$182.4M$151.6M$138.1M$123.1M$109.7M
Balance sheet
20262025202420232022
Cash and short-term investments$902.1M$714M$635.4M$376.5M$493.8M
Net receivables$3.95M$2.51M$5.5M$890K$12.9M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$948.8M$767.7M$665.8M$404.3M$512.9M
Property, plant and equipment, net$520K$940K$590K$1.5M$2.63M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.75M$8.56M$940K$1.5M$2.63M
Total assets$957.6M$776.2M$666.7M$405.8M$515.6M
Accounts payable$7.54M$17.7M$7.16M$1.35M$18.6M
Short-term debt$70K$100K$140K$1.17M$1.15M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$104.4M$68.8M$48.6M$43.3M$44.5M
Long-term debt$0.00$0.00$0.00$50K$1.22M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$550K$0.00$350K$50K$1.22M
Capital lease obligations$70K$100K$140K$1.22M$2.36M
Total liabilities$105M$68.8M$49M$43.3M$45.7M
Common stock$20K$20K$10K$10K$10K
Retained earnings-$-1.75B-$-1.24B-$-825.68M-$-566.35M-$-355.39M
Accumulated other comprehensive income (loss)$730K$1.46M$1.91M$850K$400K
Total equity$852.6M$707.5M$617.8M$362.5M$469.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$70K$100K$140K$1.22M$2.36M
Net debt-$-902.04M-$-713.87M-$-635.23M-$-375.31M-$-491.45M
Cash flow statement
20262025202420232022
Net income-$-505.61M-$-413.84M-$-259.34M-$-210.96M-$-156.73M
Depreciation and amortization$410K$380K$230K$190K$130K
Stock-based compensation$55.7M$49.5M$41.1M$32.3M$34.2M
Change in working capital$42.1M-$-12.03M$2.63M-$-10.85M$15.1M
Accounts receivable-$-1.4M$2.97M-$-4.56M$12.2M-$-11.72M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-10.25M$10.7M$5.78M-$-17.12M$16.3M
Net cash provided by operating activities-$-407.31M-$-375.87M-$-214.23M-$-188.19M-$-106.11M
Investments in property, plant and equipment-$-10K-$-760K-$-360K-$-200K-$-250K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-760K-$-360K-$-200K-$-250K
Common stock issued$596.3M$450M$472.8M$70.5M$130K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$595.8M$454.5M$472.4M$70.9M$200.1M
Net change in cash$188.1M$78.6M$258.8M-$-117.28M$93.7M
Cash at end of period$902.1M$714M$635.4M$376.5M$493.8M
Operating cash flow-$-407.31M-$-375.87M-$-214.23M-$-188.19M-$-106.11M
Capital expenditure-$-10K-$-760K-$-360K-$-200K-$-250K
Free cash flow-$-407.32M-$-376.63M-$-214.59M-$-188.39M-$-106.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immunovant, Inc.

        Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

        CEO
        Eric Venker
        Employees
        315
        Beta
        0.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Immunovant, Inc. (IMVT)?

        InvestorsCraft does not currently publish an intrinsic value for IMVT. How the IC value is calculated.

        Is IMVT undervalued?

        InvestorsCraft does not publish an undervaluation signal for IMVT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.